FACILITATING LIBTAYO ACCESS
for PD-L1-Positive NSCLC in India
Background
A 59-year-old entrepreneur from Pune was diagnosed with PD-L1-positive advanced NSCLC. Immunotherapy was considered essential to his treatment strategy.
Physician’s Recommendation
The treating oncologist recommended Libtayo (cemiplimab) based on biomarker status and international treatment guidelines. As the medicine was not readily available in India, access via NPP became the only viable option.
The Access Journey
MitoGENE was brought in to facilitate the process. The team worked closely with the treating oncologist and the hospital administration to ensure documentation accuracy and regulatory compliance.
Key steps included:
End-to-end
NPP documentation management
Liaison with EU-based suppliers for timely
availability
Logistics coordination with strict adherence to
cold-chain requirements
Customs clearance and scheduled delivery
aligned with treatment cycles
Outcome
Libtayo was successfully imported and administered as per the treatment plan. The patient tolerated therapy well and continued treatment under close medical supervision.
Broader Impact
This case reinforces how collaboration between physicians, patients, and NPP specialists like MitoGENE can bridge access gaps in advanced oncology care in India.
Disclaimer
MitoGENE facilitates patient-specific access to medicines under Named Patient Program permitted by CDSCO through Form 12B. The products mentioned are not approved for commercial sale in India. Access is strictly for personal use under physician supervision. Information provided on this website is sourced from publicly available references, and MitoGENE is not responsible for its completeness or accuracy. MitoGENE does not promote or sell any specific product and does not replace advice from qualified healthcare professionals.